|
|
Post by peppy on Apr 17, 2019 9:23:19 GMT -5
patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=17&f=G&l=50&co1=AND&d=PTXT&s1=%22K%26L+Gates%22&s2=20190416.PD.&OS=%22K%26L+Gates%22+AND+ISD/4/16/2019&RS=%22K%26L+Gates%22+AND+ISD/4/16/2019BACKGROUND Acute pain is characterized by a sudden onset and relatively short duration, and is generally treated with opioid analgesics like morphine. Morphine and similar opioid analgesics suppress the perception of pain by reducing the number of pain sensations sent by the nervous system and the brain's reaction to those pain signals. Current opioid therapy using morphine and like compounds are effective to treat pain but the side effects they produce such as addiction, somnolescence, tolerance, respiratory depression, and constipation limit their clinical use. In addition, opiates presently used in therapy such as morphine are alkaloid compounds isolated from natural sources such as the opium poppy. There are also semi-synthetic substances derived from the opium poppy, as well as and are chemically synthesized compounds including anilidopiperidines, phenylpiperidines, diphenylpropylamine derivatives, morphinan derivatives, and benzomorphan derivatives. Opioid analgesics relieve pain and inhibit nociceptive signaling by binding to opioid receptors on cells in the central and peripheral nervous systems and the gastrointestinal tract. The analgesic effects of opioids are due to decreased perception of pain, decreased reaction to pain and increased resistance to pain. Known opioid receptors include mu (.mu.), delta (.delta.) and kappa (.kappa.). Opioid receptor agonists, including morphine, the enkephalins, and the dynorphins, bind to these receptors. The most commonly studied opioid receptor modulated is the .mu. opioid receptor. However, kappa opioid receptor agonists have been shown to be effective and potent analgesics, but their usefulness in humans is limited due to their psychomimetic and dysphoric effects. Delta (.delta.) opioid receptor agonists are known to produce analgesic effects with lesser magnitude side effects than .mu. analgesics. For example, delta analgesics induce less tolerance and physical dependence, do not depress respiration, and cause few or no adverse gastrointestinal effects, including constipation. However, delta opioid receptor agonists can produce seizures. Moreover, in some animal experiments, delta opioid agonists can produce an effective and potent analgesic effect when administered intrathecally or by intracerebroventricular injection. However; these routes of administration are not practical for treating patients. Therefore, there is still a need in the medical art to develop new treatments for pain which would facilitate patient therapy and reduce or eliminate unwanted side effects. Additionally, there is a need for the identification and development of new compounds and compositions that do not cross the blood-brain barrier and effectively alleviate pain without activating opioid receptors in the central nervous system. mango An embodiment includes an inhalable, analgesic composition comprising microparticles of a diketopiperazine and a peptide comprising less than 20 amino acids; wherein said composition is effective in relieving pain. In an embodiment the peptide comprises one or more of: glycine, alanine, valine, methionine, phenylalanine, serine, threonine, asparagine, glutamine, cysteine, lysine, histidine, aspartic acid, glutamic acid, leucine, isoleucine, norleucine, tyrosine, serine, proline, and tryptophan. In some embodiments, the peptide comprises at least 3 amino acids, wherein each of those 3 amino acids is: arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, or tryptophan. In embodiments the peptide is greater than 0.25% of the weight of a dry powder composition. In certain embodiments the peptide can comprises an amino acid sequence of from three to eight amino acids in length. In embodiments the peptide can comprise one of the following sequences: (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1), (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2), Trp-(D)Pro-Ser-Phe-NH.sub.2 (SEQ ID NO: 3), Trp-(D)Ser-Ser-Phe-NH.sub.2 (SEQ ID NO: 4); Dmt-D-Arg-Phe-Lys-NH.sub.2 (SEQ ID NO: 5), Ac-His-(D)Phe-Arg-(D)Trp-Gly-NH.sub.2 (SEQ ID NO: 6), and Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH.sub.2 (SEQ ID NO:7). In embodiments the peptide can be an opioid receptor agonist. In embodiments the peptide can bind to the .mu. opioid receptor, .delta. opioid receptor, or .kappa. opioid receptors, or combinations of receptors thereof of cells in the central or peripheral nervous systems. weehaw, ridem. mango See the GRANT?
|
|
|
|
Post by rravis1914 on Apr 17, 2019 9:50:36 GMT -5
Peppy,
Appreciate your find. On the surface it looks like it could be one of the biggest things to hit the market.
Do you have any thoughts as to its present status and when could it be a commercial product?
RRAVIS1914 |
|
|
|
Post by peppy on Apr 17, 2019 10:03:58 GMT -5
I was just looking for the bucket list MNKD put out as to the compounds. Wondering if it is a form of the stuff/medication that is presently being injected IM for these people, chemical formula wise. mango Bandito we need you. We seem to have a list of "ingredients" Oh and numero ONO an analgesic composition. Not Narcotic. an embodiment the peptide comprises one or more of: glycine, alanine, valine, methionine, phenylalanine, serine, threonine, asparagine, glutamine, cysteine, lysine, histidine, aspartic acid, glutamic acid, leucine, isoleucine, norleucine, tyrosine, serine, proline, and tryptophan. In some embodiments, the peptide comprises at least 3 amino acids, wherein each of those 3 amino acids is: arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, or tryptophan. In embodiments the peptide is greater than 0.25% of the weight of a dry powder composition. |
|
|
|
Post by mango on Apr 17, 2019 10:22:48 GMT -5
I was just looking for the bucket list MNKD put out as to the compounds. Wondering if it is a form of the stuff/medication that is presently being injected IM for these people, chemical formula wise. mango Bandito we need you. We seem to have a list of "ingredients" Oh and numero ONO an analgesic composition. Not Narcotic. an embodiment the peptide comprises one or more of: glycine, alanine, valine, methionine, phenylalanine, serine, threonine, asparagine, glutamine, cysteine, lysine, histidine, aspartic acid, glutamic acid, leucine, isoleucine, norleucine, tyrosine, serine, proline, and tryptophan. In some embodiments, the peptide comprises at least 3 amino acids, wherein each of those 3 amino acids is: arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, or tryptophan. In embodiments the peptide is greater than 0.25% of the weight of a dry powder composition. Looks like a NCE for pain? Bucket 4 |
|
|
|
Post by brentie on Apr 17, 2019 10:25:28 GMT -5
Peppy,
Appreciate your find. On the surface it looks like it could be one of the biggest things to hit the market.
Do you have any thoughts as to its present status and when could it be a commercial product?
RRAVIS1914 I'm not Peppy but I hope you won't mind if I comment anyways. I was surprised to see that they filed this about two years ago because a year before that it sounded like the MNKD/ Torrey Pines pain medication was dead.... What is going on with deals involving Torrey Pine, Technovax, Colby, Rose Pharma & Tolero? What is happening with the “cricket” inhaler? The so‐called “cricket” is a disposable, single use version of the inhalation device used for other products like Afrezza. There are many potential applications for this device, including MannKind’s recently announced development program in epinephrine for anaphylaxis. Torrey Pines was an opportunity we could not pursue at this time due to program risk, high costs and prolonged timelines. As far as specific deals involving other companies, MannKind will be providing updates as significant events unfold. www.mannkindcorp.com/Collateral/Documents/English-US/MNKD%202%203%2016%20Investor%20Call%20FAQ%20v2%209%2016%20FINAL.pdfI really hope something comes from this because I, like you, thought that this could be huge. The link no longer works but this is an article from 2012... PORT ST. LUCIE — Torrey Pines Institute for Molecular Studies could begin testing a new pain medication on humans as early as 2013, Torrey Pines founder Dr. Richard Houghten said Tuesday. The drug would be a breakthrough in pain medication at a time when state and local legislators are trying to curb addiction to prescription drugs. The drug is designed to provide quick pain relief while eliminating side effects such as addiction, respiratory depression and adverse psychological consequences. "In Port St. Lucie because of what the state, the city and the county and whatnot have done, we've been able to develop these methods so that we're now to the point where we have advanced compound that will be going into humans, going into man in 2013," Houghten told guests gathered at the Economic Development Council of St. Lucie monthly luncheon. Torrey Pines opened a $40 million, 100,000-square-foot facility in January 2009 and has hired about 107 of the 189 jobs promised by 2016. The nonprofit has plans to hire another 13 before June, Houghten said. Torrey Pines has more room to operate and do research now that Vaccine & Gene Therapy Institute of Florida has moved into its own building down the street in January. VGTI had occupied the third floor of Torrey Pines' building. While both nonprofits showed gratitude and collaborated with one another to make the situation work, both are happy to have their own space. After the lunch, Houghten expanded on the new drug's possibilities. "It's actually pretty marvelous," Houghten said. "You can't (overdose) on this drug." The drug is being developed in partnership with Mannkind Corp., which has created a small device that allows people to inhale medicine. By inhaling, the medicine can relieve pain quicker than through pill form, Houghten said. "Our pain compound, if it all works out, ... if you can take that pain compound and just inhale within just 30 seconds to a minute, your pain will be alleviated," Houghten said. "So you can see that that can be a real important step." The drug has been tested on two separate animal groups and Houghten said the drug will be tested on a third before going before the U.S. Food and Drug Administration, which must give approval for human trials. Houghten said the unique nature of the drug could make it easier to get approval. "You never really quite know," he said. "Right now, everything's looking really good. ... We can't get a high enough dose that causes a problem." Patients also do not build up a tolerance to the medicine, whereas other pain relievers require patients to take more and more to get the same effect. Houghten said he is thrilled with the drug's progress. "In reality is if it's 2014 (before human testing), I'm still going to be happy," Houghten said. "I don't think it's going to be a problem with the FDA. It's very simple what we want to do, so we can show them clearly here's the effective dose, here's the toxic dose. That's 90 percent of it right there. It's effective and it's not toxic." |
|
|
|
Post by peppy on Apr 17, 2019 10:28:45 GMT -5
put up with me here, just looking. Prescription medications used to relieve the pain of migraine include triptans (a class of drugs), for example: sumatriptan (Imitrex, Alsuma, Imitrex STATdose System, Sumavel DosePro, Zecuity, Treximet) rizatriptan (Maxalt, Maxalt-MLT) eletriptan (Relpax) zolmitriptan (Zomig, Zomig-ZMT) naratriptan Amerge) almotriptan (Axert) frovatriptan (Frova) Erenumab (Aimovig) is a new class of drug called a calcitonin gene-related peptide receptor (CGRP-R) antagonist approved in 2018 to treat migraine. It is a monthy injection used to prevent migraines. www.medicinenet.com/migraine/article.htm#migraine_headache_definition_and_factsmigraine.com/migraine-treatment/triptans/Triptans are a class of medications that are selective serotonin 5-hydroxytryptamine (5-HT)(1B/1D) receptor agonists. Triptans are primarily used in the acute treatment of moderate to severe migraine. Triptans, which first came to market in the early 1990s, come in different formulations, both brand and generic.1 These include oral medications such as tablets, capsules and quick dissolving tablets, subcutaneous injections, nasal sprays, and transdermal patch. In some embodiments, the peptide comprises at least 3 amino acids, wherein each of those 3 amino acids is: arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, or tryptophan. In embodiments the peptide is greater than 0.25% of the weight of a dry powder composition. TRIP = 3. Liane, ?  |
|
|
|
Post by peppy on Apr 17, 2019 10:30:52 GMT -5
oh, brentie It is Torrey pines? What's your take? Nothing to see here? Man an analgesic. |
|
|
|
Post by brentie on Apr 17, 2019 10:48:10 GMT -5
oh, brentie It is Torrey pines? What's your take? Nothing to see here? Man an analgesic. Yeah it says Torrey Pines and MannKind are the applicants on the link you posted. It would be great but I'll have to see it to believe it. However, a lot has changed since that Q&A in 2016.🤞 |
|
|
|
Post by peppy on Apr 17, 2019 10:50:53 GMT -5
oh, brentie It is Torrey pines? What's your take? Nothing to see here? Man an analgesic. Yeah it says Torrey Pines and MannKind are the applicants on the link you posted. It would be great but I'll have to see it to believe it. However, a lot has changed since that Q&A in 2016.🤞 Good point. Let's put this on the list for the questions and at answers at the shareholders meeting. The market doesn't seem to be going wild. all we need is Bayer aspirin, now Monsanto shorting the hell out of us too. |
|
|
|
Post by peppy on Apr 17, 2019 11:18:14 GMT -5
patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=17&f=G&l=50&co1=AND&d=PTXT&s1=%22K%26L+Gates%22&s2=20190416.PD.&OS=%22K%26L+Gates%22+AND+ISD/4/16/2019&RS=%22K%26L+Gates%22+AND+ISD/4/16/2019BACKGROUND Acute pain is characterized by a sudden onset and relatively short duration, and is generally treated with opioid analgesics like morphine. Morphine and similar opioid analgesics suppress the perception of pain by reducing the number of pain sensations sent by the nervous system and the brain's reaction to those pain signals. Current opioid therapy using morphine and like compounds are effective to treat pain but the side effects they produce such as addiction, somnolescence, tolerance, respiratory depression, and constipation limit their clinical use. In addition, opiates presently used in therapy such as morphine are alkaloid compounds isolated from natural sources such as the opium poppy. There are also semi-synthetic substances derived from the opium poppy, as well as and are chemically synthesized compounds including anilidopiperidines, phenylpiperidines, diphenylpropylamine derivatives, morphinan derivatives, and benzomorphan derivatives. Opioid analgesics relieve pain and inhibit nociceptive signaling by binding to opioid receptors on cells in the central and peripheral nervous systems and the gastrointestinal tract. The analgesic effects of opioids are due to decreased perception of pain, decreased reaction to pain and increased resistance to pain. Known opioid receptors include mu (.mu.), delta (.delta.) and kappa (.kappa.). Opioid receptor agonists, including morphine, the enkephalins, and the dynorphins, bind to these receptors. The most commonly studied opioid receptor modulated is the .mu. opioid receptor. However, kappa opioid receptor agonists have been shown to be effective and potent analgesics, but their usefulness in humans is limited due to their psychomimetic and dysphoric effects. Delta (.delta.) opioid receptor agonists are known to produce analgesic effects with lesser magnitude side effects than .mu. analgesics. For example, delta analgesics induce less tolerance and physical dependence, do not depress respiration, and cause few or no adverse gastrointestinal effects, including constipation. However, delta opioid receptor agonists can produce seizures. Moreover, in some animal experiments, delta opioid agonists can produce an effective and potent analgesic effect when administered intrathecally or by intracerebroventricular injection. However; these routes of administration are not practical for treating patients. Therefore, there is still a need in the medical art to develop new treatments for pain which would facilitate patient therapy and reduce or eliminate unwanted side effects. Additionally, there is a need for the identification and development of new compounds and compositions that do not cross the blood-brain barrier and effectively alleviate pain without activating opioid receptors in the central nervous system. mango An embodiment includes an inhalable, analgesic composition comprising microparticles of a diketopiperazine and a peptide comprising less than 20 amino acids; wherein said composition is effective in relieving pain. In an embodiment the peptide comprises one or more of: glycine, alanine, valine, methionine, phenylalanine, serine, threonine, asparagine, glutamine, cysteine, lysine, histidine, aspartic acid, glutamic acid, leucine, isoleucine, norleucine, tyrosine, serine, proline, and tryptophan. In some embodiments, the peptide comprises at least 3 amino acids, wherein each of those 3 amino acids is: arginine, phenylalanine, leucine, isoleucine, norleucine, tyrosine, serine, proline, or tryptophan. In embodiments the peptide is greater than 0.25% of the weight of a dry powder composition. In certain embodiments the peptide can comprises an amino acid sequence of from three to eight amino acids in length. In embodiments the peptide can comprise one of the following sequences: (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1), (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2), Trp-(D)Pro-Ser-Phe-NH.sub.2 (SEQ ID NO: 3), Trp-(D)Ser-Ser-Phe-NH.sub.2 (SEQ ID NO: 4); Dmt-D-Arg-Phe-Lys-NH.sub.2 (SEQ ID NO: 5), Ac-His-(D)Phe-Arg-(D)Trp-Gly-NH.sub.2 (SEQ ID NO: 6), and Ac-Nle-Gln-His-(D)Phe-Arg-(D)Trp-Gly-NH.sub.2 (SEQ ID NO:7). In embodiments the peptide can be an opioid receptor agonist. In embodiments the peptide can bind to the .mu. opioid receptor, .delta. opioid receptor, or .kappa. opioid receptors, or combinations of receptors thereof of cells in the central or peripheral nervous systems. weehaw, ridem. mango See the GRANT? Mango, do you see a Grant Statement? A Grant to what entities? |
|
|
|
Post by peppy on Apr 17, 2019 11:51:05 GMT -5
I am sorry, I am sorry.
MannKind Corporation
TORREY PINES INSTITUTE FOR MOLECULAR STUDIES
Westlake Village
Port St. Lucie
CA
FL
US
US
Assignee: MannKind Corporation (Westlake Village, CA)
Family ID: 1000003948222
Appl. No.: 15/439,813
Filed: February 22, 2017
United States Patent 10,258,664
Leone-Bay , et al. April 16, 2019
|
|
|
|
Post by porkini on Apr 17, 2019 12:05:47 GMT -5
I am sorry, I am sorry. MannKind Corporation TORREY PINES INSTITUTE FOR MOLECULAR STUDIES Westlake Village Port St. Lucie CA FL US US Assignee: MannKind Corporation (Westlake Village, CA) Family ID: 1000003948222 Appl. No.: 15/439,813 Filed: February 22, 2017 United States Patent 10,258,664 Leone-Bay , et al. April 16, 2019 I actually thought this view was easier on the eyes: Pain Patent ImagesAlso, and I often accuse myself of being dense, but all I see is a lot of people named "Grant" in the references and this: |
|
|
|
Post by peppy on Apr 17, 2019 12:14:41 GMT -5
I am sorry, I am sorry. MannKind Corporation TORREY PINES INSTITUTE FOR MOLECULAR STUDIES Westlake Village Port St. Lucie CA FL US US Assignee: MannKind Corporation (Westlake Village, CA) Family ID: 1000003948222 Appl. No.: 15/439,813 Filed: February 22, 2017 United States Patent 10,258,664 Leone-Bay , et al. April 16, 2019 I actually thought this view was easier on the eyes: Pain Patent ImagesAlso, and I often accuse myself of being dense, but all I see is a lot of people named "Grant" in the references and this: Thank you. I'll just take some deep breaths.  |
|
|
|
Post by mymann on Apr 17, 2019 12:18:40 GMT -5
Great finding, lets not get too excited. As in past, we get all worked up and nothing comes about. Just like the shipment to Dubai.
|
|
|
|
Post by ktim on Apr 17, 2019 13:30:50 GMT -5
Great finding, lets not get too excited. As in past, we get all worked up and nothing comes about. Just like the shipment to Dubai. I had nearly forgotten about the boat to Dubai. You have to give those trying to do upside stock manipulation credit for creativeness. The shorts never come up with truly interesting/funny things like that. |
|
